Levodopa in the treatment of Parkinson's disease: current controversies.

نویسندگان

  • C Warren Olanow
  • Yves Agid
  • Yoshi Mizuno
  • Alberto Albanese
  • Ubaldo Bonuccelli
  • Philip Damier
  • Justo De Yebenes
  • Oscar Gershanik
  • Mark Guttman
  • F Grandas
  • Mark Hallett
  • Ole Hornykiewicz
  • Peter Jenner
  • R Katzenschlager
  • William J Langston
  • Peter LeWitt
  • Eldad Melamed
  • M A Mena
  • P P Michel
  • Catherine Mytilineou
  • Jose A Obeso
  • Werner Poewe
  • Niall Quinn
  • R Raisman-Vozari
  • Ali H Rajput
  • Olivier Rascol
  • Christina Sampaio
  • Fabrizio Stocchi
چکیده

Levodopa is the most effective symptomatic agent in the treatment of Parkinson's disease (PD) and the "gold standard" against which new agents must be compared. However, there remain two areas of controversy: (1) whether levodopa is toxic, and (2) whether levodopa directly causes motor complications. Levodopa is toxic to cultured dopamine neurons, and this may be a problem in PD where there is evidence of oxidative stress in the nigra. However, there is little firm evidence to suggest that levodopa is toxic in vivo or in PD. Clinical trials have not clarified this situation. Levodopa is also associated with motor complications. Increasing evidence suggests that they are related, at least in part, to the short half-life of the drug (and its potential to induce pulsatile stimulation of dopamine receptors) rather than to specific properties of the molecule. Treatment strategies that provide more continuous stimulation of dopamine receptors provide reduced motor complications in MPTP monkeys and PD patients. These studies raise the possibility that more continuous and physiological delivery of levodopa might reduce the risk of motor complications. Clinical trials to test this hypothesis are underway. We review current evidence relating to these areas of controversy.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

THERMODYNAMIC STUDY OF LEVODOPA DRUG ADSORPTION ON ZIGZAG BORON NITRIDE NANOTUBES BY DENSITY FUNCTIONAL THEORY (DFT) METHOD

Background & Aims: The overall goal of utilizing nanotubes in drug delivery is to treat a disease effectively with minimum side effects and control the drug release rate. With common methods of taking the medication, such as orally and intravenously, the drug is distributed throughout the body, and the whole body is affected by the drug, and adverse side effects occur. With the development of n...

متن کامل

'Bad guys' among the antiparkinsonian drugs.

The first effective drugs for Parkinson's disease (PD) were anticholinergics, introduced at the end of 19.th century by Charcot. Since the introduction of levodopa in the sixties of the previous century, many new drugs have emerged for the treatment of Parkinson's disease: dopamine agonists (ergot as well as non-ergot, bromocriptine, pergolide, mirapexine, ropinirole), MAO B inhibitors (selegil...

متن کامل

Diabetes Increases the Incidence of Levodopa-Induced Dyskinesia in Parkinson’s Disease; A Case-Control Study

Background and Objective: Dyskinesia is a debilitating complication of Parkinsonchr('39')s disease (PD), which appears due to some known risk factors. The effect of diabetes and high plasma glucose on the manifestation of dyskinesia has been evaluated in just a few previous reports. The current study aimed to assess the mentioned correlation. Materials and Methods: In this case-control study, ...

متن کامل

Betaine protects cerebellum from oxidative stress following levodopa and benserazide administration in rats

Objective(s): The aim of the present study was to evaluate antioxidant and methyl donor effects of betaine in cerebellum following levodopa and benserazide administration in rats. Materials and Methods: Sprague-Dawley male rats were treated with levodopa (LD), betaine (Bet), levodopa plus betaine (LD/Bet), levodopa plus benserazide (LD/Ben), levodopa plus betaine-benserazide (LD/Bet-Ben), and t...

متن کامل

Levodopa in the treatment of Parkinson's disease: current status and new developments.

Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease (PD). Oral levodopa has been widely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor (DDCI), which reduces many treatment complications, extending its half-life and increasing levodopa availability to the brain. Entacapone, a catechol-O-...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Movement disorders : official journal of the Movement Disorder Society

دوره 19 9  شماره 

صفحات  -

تاریخ انتشار 1977